Holen Sie sich die Stockscreener-App
1.46
0.68%
-0.01
Schlusskurs vom Vortag:
$1.47
Offen:
$1.47
24-Stunden-Volumen:
189.05K
Relative Volume:
0.05
Marktkapitalisierung:
$12.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.92M
KGV:
-0.3418
EPS:
-4.2716
Netto-Cashflow:
$-20.51M
1W Leistung:
-9.03%
1M Leistung:
-28.08%
6M Leistung:
+2.82%
1J Leistung:
-27.00%
1-Tages-Spanne:
$1.46
$1.52
1-Wochen-Bereich:
$1.46
$1.61
52-Wochen-Spanne:
$0.82
$3.79
Biovie Inc Stock (BIVI) Company Profile
Firmenname
Biovie Inc
Sektor
Branche
Telefon
775-888-3162
Adresse
680 W NYE LANE, CARSON CITY
Compare BIVI vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
1.46 | 13.69M | 0 | -19.92M | -20.51M | -4.2716 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-15 | Eingeleitet | B. Riley Securities | Buy |
Biovie Inc Aktie (BIVI) Neueste Nachrichten
BioVie (BIVI) Stock Analysis Report | Financials & Insights - Benzinga France
BioVie Inc. (BIVI) Stock Price, News, Quote & History - Yahoo! Finance Canada
BioVie Inc. (BIVIW) Stock Price, News, Quote & History - Yahoo! Finance Canada
BioVie Inc. (BIVI) Latest Stock News & HeadlinesYahoo Finance - Yahoo! Finance Canada
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global - guardonline.com
Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results - ACCESS Newswire
BIVI 6-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages BioVie (BIVI) Investors with Substantial Losses to Contact its Attorneys Before Mar. 19th Deadline in Securities Fraud Class Action Over Failed Phase 3 Clinical Trial - TMX Newsfile
BioVie Deadline Alert - TMX Newsfile
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global - Eagle-Tribune
Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - Yahoo Finance
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long CovidSlideshow (NASDAQ:BIVI) 2026-09-17 - Seeking Alpha
BIVI Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus as Shares Slip 2.29%Product Revenue Analysis - careplusvn.com
Biovie Inc (BIVI) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
What's Going On With BioVie Stock on Tuesday?BioVie (NASDAQ:BIVI) - Benzinga
BioVie Shares Fall 9.7% After Long COVID Trial Misses Statistical Significance in Full Population - Yahoo Finance
Why is BioVie stock sliding today? By Investing.com - Investing.com Canada
BioVie reports phase 2 long COVID trial results By Investing.com - Investing.com Australia
BioVie Plans Phase III Study After Long COVID Drug Shows Subgroup Signals - insights.citeline.com
BioVie Reports Topline Phase 2 ADDRESS-LC Results Showing Bezisterim Benefits in Long COVID Subgroups with High Symptom Burden - Quiver Quantitative
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - Yahoo Finance
BioVie Phase 2 trial shows bezisterim eases fatigue, cognitive symptoms in severe Long COVID cases - Proactive financial news
Biovie Inc (BIVI) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
BioVie to Host Conference Call to Discuss Topline Data from - GlobeNewswire
BioVie Signs ATM Sales Agreement to Offer Up to $6.46 Million in Stock - Minichart
Form 8K Biovie Inc For: 14 September By Investing.com - Investing.com Canada
BioVie Inc Files for Atm Offering of up to Ab - Moomoo
BIVI 8-K FilingsBioVie, Inc. SEC 8-K - Stock Titan
How much new stock can BioVie (NASDAQ: BIVI) now sell into the market? - Stock Titan
Biovie seeks FDA meeting to plan Phase 3 trial for Parkinson’s drug candidate - Parkinson's News Today
Jane Street Group Expands BioVie Inc (BIVI) Stake by Over 1,100% - GuruFocus
Market movers: Novartis, Qualcomm, EchoStar, BioVie... - proactiveinvestors.com
BioVie advances bezisterim Phase 3 Parkinson’s trial - grafa.com
BioVie advances Parkinson’s Phase 3 trial plans after positive Phase 2 results and FDA engagement. - Pluang
BioVie advances Parkinson’s Phase 3 development program with FDA engagement - Yahoo Finance
BioVie Announces Update to Parkinson’s Phase 3 Development Program - markets.businessinsider.com
BioVie seeks FDA feedback on a proposed Parkinson’s trial of about 175 patients. - Stock Titan
BIVI Form 4 FilingsBioVie, Inc. SEC Form 4 - Stock Titan
Biovie Stock Price Forecast. Should You Buy BIVI? - StockInvest.us
Jane Street reports over 5% stake in BioVie (BIVI) - stocktitan.net
Small cap wrap: Alvopetro, Royal Road Minerals, Nextech3D.ai, TNR Gold... - Proactive financial news
Market movers: PG&E, Aon, Eli Lilly, BioVie... - Proactive financial news
BioVie completes final patient visit in Phase 2 Long COVID trial, topline results due by September 2026 - Pluang
BioVie (BIVI) Completes Final Visit in ADDRESS-LC Phase 2 Trial for Long COVID Neurological Symptoms - GuruFocus
BioVie Announces Completion of Treatment Phase of - GlobeNewswire
Dow falls as US strikes Iran, rate-hike bets jump - proactiveinvestors.co.uk
Biovie Inc (BIVI) Key Financial Ratios – Valuation, Profitability & More - Value Research
BioVie completes final patient visit in Phase 2 Long COVID trial - Proactive financial news
Price to earnings forward of BioVie Inc. – BOATS:BIVIW - TradingView
Finanzdaten der Biovie Inc-Aktie (BIVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biovie Inc-Aktie (BIVI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chappell Amy Suzon | Director |
Aug 28 '26 |
Buy |
2.16 |
727 |
1,570 |
727 |
| KIM JOANNE WENDY | Chief Financial Officer |
Aug 28 '26 |
Buy |
2.18 |
2,500 |
5,450 |
3,441 |
| DO CUONG V | President & CEO |
Aug 27 '26 |
Buy |
2.08 |
15,210 |
31,637 |
16,117 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):